Factorial study of the effect of n–3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
Open Access
- 1 June 2006
- journal article
- research article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 84 (1) , 37-43
Abstract
Background: Disturbed HDL metabolism in insulin-resistant, obese subjects may account for an increased risk of cardiovascular disease. Fish oils and atorvastatin increase plasma HDL cholesterol, but the underlying mechanisms responsible for this change are not fully understood. Objective: We studied the independent and combined effects of fish oils and atorvastatin on the metabolism of HDL apolipoprotein A-I (apo A-I) and HDL apo A-II in obese men. Design: We conducted a 6-wk randomized, placebo-controlled, 2 × 2 factorial intervention study of the effects of fish oils (4 g/d) and atorvastatin (40 mg/d) on the kinetics of HDL apo A-I and HDL apo A-II in 48 obese men with dyslipidemia with intravenous administration of [d3]-leucine. Isotopic enrichments of apo A-I and apo A-II were measured with gas chromatography–mass spectrometry with kinetic parameters derived from a multicompartmental model (SAAM II). Results: Fish oils and atorvastatin significantly decreased plasma triacylglycerols and increased HDL cholesterol and HDL2 cholesterol (P < 0.05 for main effects). A significant (P < 0.02) main effect of fish oils was observed in decreasing the fractional catabolic rate of HDL apo A-I and HDL apo A-II. This was coupled with a significant decrease in the corresponding production rates, accounting for a lack of treatment effect on plasma concentrations of apo A-I and apo A-II. Atorvastatin did not significantly alter the concentrations or kinetic parameters of HDL apo A-I and HDL apo A-II. None of the treatments altered insulin resistance. Conclusions: Fish oils, but not atorvastatin, influence HDL metabolism chiefly by decreasing both the catabolism and production of HDL apo A-I and HDL apo A-II in insulin-resistant obese men. Addition of atorvastatin to treatment with fish oils had no additional effect on HDL kinetics compared with fish oils alone.Keywords
This publication has 34 references indexed in Scilit:
- High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle KineticsThe Journal of Clinical Endocrinology & Metabolism, 2006
- Obesity, Metabolic Syndrome, and Cardiovascular DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2004
- Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic SyndromeDiabetes, 2003
- Atheroprotective Effects of High-Density LipoproteinsAnnual Review of Medicine, 2003
- Apolipoprotein A-II, HDL metabolism and atherosclerosisAtherosclerosis, 2002
- Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentrationMetabolism, 2002
- Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the CirculationArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- High-density apolipoprotein A-I and A-II kinetics in relation to regional adiposityMetabolism, 1992